+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (X-Ray Devices, Ultrasound Devices, MRI, CT, Others), By Application (Hospitals, Diagnostic Centers, Clinics, Others), By End User (Radiology Departments, Cardiology Departments, Oncology Centers, Research Institutions), By Technology Sophistication (High-End/Advanced Systems, Mid-Range Systems, Entry-Level/Portable Systems), By Service Model (Equipment Sales, Rental/Leasing Services, Managed Equipment Services), and Regional Forecast, 2026-2034
The global medical laboratory diagnostic imaging equipment market was valued at USD 51.3 billion in 2025 and is estimated at USD 53.4 billion in 2026. The market is projected to reach USD 74.4 billion by 2034, representing a 4.2% CAGR during 2026–2034.
Diagnostic imaging equipment spans X-ray, ultrasound, magnetic resonance imaging, computed tomography and other advanced modalities used to visualize anatomy and support diagnosis, treatment planning, monitoring and image-guided care. WHO recognizes medical imaging as central to modern diagnosis and treatment, while also noting that equipment affordability and trained-workforce availability remain major access constraints in many low- and lower-middle-income countries.
The commercial market is being reshaped by a dual investment cycle: replacement of mature installed systems in developed healthcare networks and capacity expansion in markets where access remains below clinical need. OECD’s 2025 data show that CT, MRI and PET availability has increased rapidly across many member countries, while use of CT and MRI continued to rise in several countries through 2023. This keeps scanner utilization, throughput and replacement planning central to hospital and diagnostic-center capital budgets.
Technology competition increasingly centers on image quality, dose management, scan speed, automation, AI-enabled workflow and total lifecycle economics. FDA’s current AI-enabled medical-device list includes a large and continuing flow of radiology authorizations, while recent 2025–2026 clearances and launches from Siemens Healthineers, GE HealthCare and Philips show how photon-counting CT, AI-assisted cardiac CT, workflow-accelerated MRI and high-volume ultrasound are moving into commercial deployment.
Source: OECD Health at a Glance 2025; WHO medical imaging; FDA Medical X-ray Imaging; FDA AI-enabled medical devices.
The study defines the global medical laboratory diagnostic imaging equipment market market by the equipment, application, end-user and technology boundaries listed below. The scope is structured to keep market sizing consistent with the commercial systems and services included in the syndicated study.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD billion |
| By Type | X-Ray Devices; Ultrasound Devices; MRI; CT; Others |
| By Application | Hospitals; Diagnostic Centers; Clinics; Others |
| By End User | Radiology Departments; Cardiology Departments; Oncology Centers; Research Institutions |
| By Technology Sophistication | High-End/Advanced Systems; Mid-Range Systems; Entry-Level/Portable Systems |
| By Service Model | Equipment Sales; Rental/Leasing Services; Managed Equipment Services |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Mexico; Germany; United Kingdom; France; Italy; Spain; China; Japan; India; South Korea; Australia; Brazil; GCC countries; South Africa and other major markets |
| Key Market Players | Siemens Healthineers; GE HealthCare; Philips Healthcare; Canon Medical Systems Corporation; Shimadzu Corporation; FUJIFILM Holdings Corporation; Hologic, Inc.; Carestream Health; Mindray Medical International; Samsung Medison; Hitachi Medical; Konica Minolta, Inc.; Analogic Corporation; Planmeca Oy; MR Solutions Ltd. |
The market includes capital diagnostic-imaging equipment and related system configurations used by hospitals, diagnostic centers, clinics and specialist departments to acquire medical images for diagnosis, monitoring, planning and research. The defined equipment scope includes X-ray, ultrasound, MRI, CT and other imaging platforms represented in the study segmentation.
The market excludes stand-alone contrast agents, radiopharmaceuticals, image-reading professional services and unrelated laboratory analyzers. Software and AI are included when embedded in, sold with or directly supporting the commercial imaging platform; stand-alone enterprise software is treated as an enabling factor unless it forms part of the equipment transaction or managed-service arrangement.
OECD reported that combined CT, MRI and PET use exceeded 370 exams per 1,000 population in several high-use countries in 2023. It also found that CT and MRI use continued to increase across multiple countries over the 2013–2023 period, supporting ongoing investment in throughput, replacement and additional imaging capacity.
Manufacturers increasingly compete through upgradeable software, reconstruction algorithms, AI-assisted workflow and detector or magnet improvements that can enhance productivity without requiring every facility to replace its entire installed base. This creates a mixed market of new system sales, upgrade packages and service contracts.
MRI, CT and other advanced systems require major capital expenditure together with site preparation, maintenance, software upgrades and trained staff. OECD notes that diagnostic technologies are major health-system cost drivers and that too many scanners can encourage low-value use, while too few create access and waiting-time problems. Procurement therefore depends on utilization planning as much as clinical capability.
FDA notes that CT, radiography and fluoroscopy use ionizing radiation and emphasizes justification and optimization of exposure. This keeps low-dose acquisition, dose monitoring, detector efficiency and reconstruction technology commercially important, particularly for facilities with high CT volumes or pediatric and repeated-imaging populations.
WHO identifies shortages of healthcare workers trained to use imaging equipment as a constraint in many lower-resource settings. Workflow automation, protocol standardization, remote support and AI-assisted acquisition are therefore being positioned not only as performance features but also as tools to improve consistency when specialist staff are scarce.
Source: OECD Diagnostic technologies 2025; WHO medical imaging; FDA Medical X-ray Imaging.
Siemens Healthineers received FDA clearance in March 2025 for an expanded Naeotom Alpha class that included both dual-source and single-source photon-counting CT systems. By September 2025, Siemens stated that more than two million patients worldwide had been scanned using its photon-counting CT technology, indicating meaningful clinical adoption beyond initial reference sites.
FDA’s AI-enabled medical-device list shows continuous radiology authorization activity across CT, MRI, ultrasound and image-analysis software. Manufacturers are embedding automation into patient positioning, acquisition, reconstruction, protocol selection and image review, making software capability an increasingly important part of hardware differentiation.
Philips launched SmartSpeed Precise in 2025 with dual-AI engines and workflow software designed to improve scan speed and image quality across its 1.5T and 3.0T portfolio. The commercial opportunity is strongest where providers need to increase examinations per installed scanner without proportionally adding staff or magnet capacity.
Compact ultrasound and mobile imaging systems extend diagnostics into emergency, ambulatory and decentralized care. Philips launched Alturion in July 2026 after FDA 510(k) clearance and CE marking, targeting high-volume clinical environments with AI-powered workflows; this reinforces the shift toward systems that combine mobility or smaller footprints with automated operation.
Large provider networks increasingly evaluate uptime, upgrades, cybersecurity, fleet visibility and lifecycle cost alongside purchase price. Managed equipment arrangements can reduce upfront capital pressure and keep software and hardware closer to current technical standards, particularly for multi-site hospital and diagnostic-center networks.
Source: Siemens Healthineers photon-counting CT; Siemens U.S. installation; FDA AI-enabled devices; Philips SmartSpeed Precise; Philips Alturion.
Diagnostic imaging technology is shifting toward higher information density, faster acquisition, lower dose where ionizing radiation is used, greater portability and software-defined workflow. These changes affect both the premium-system mix and the economics of installed fleets.
Photon-counting CT counts individual X-ray photons and can provide high-resolution images with material information. Commercialization is expanding beyond first-generation flagship systems, increasing competitive pressure across premium CT portfolios.
AI-assisted reconstruction and protocol automation are reducing scan-time constraints and can raise patient throughput on existing magnets. Helium-efficient and helium-free magnet concepts also address lifecycle risk and siting considerations.
Ultrasound benefits from lower infrastructure requirements and absence of ionizing radiation. AI-assisted measurements and workflow guidance can extend advanced capability into busy departments and smaller care settings.
Imaging platforms increasingly connect to enterprise data, remote service, fleet-management and AI ecosystems. This shifts differentiation toward software lifecycle, cybersecurity, interoperability and upgradeability in addition to core imaging hardware.
Source: FDA AI-enabled medical devices; FDA PCCP guidance; Siemens Healthineers; Philips.
Equipment-type demand is shaped by clinical use, acquisition cost, installed-base size, replacement cycles and modality-specific innovation. MRI leads the value mix in the syndicated segmentation, while CT, X-ray and ultrasound each retain distinct high-volume roles.
MRI represents the leading equipment type in the study’s current market structure. Its position reflects high system value and broad use in neurology, musculoskeletal imaging, oncology and other soft-tissue applications without ionizing radiation. Productivity improvements, faster reconstruction and magnet innovations are supporting replacement and premiumization.
CT remains essential for emergency, trauma, chest, oncology and cardiovascular imaging because of its speed and broad clinical availability. Photon-counting, spectral imaging, cardiac workflow automation and dose optimization are increasing the value of premium CT replacements.
Digital radiography remains a foundational imaging modality with a large installed base and high examination volume. Growth is driven by detector upgrades, mobile systems, workflow automation and replacement of older analog or early digital platforms.
Ultrasound benefits from lower infrastructure requirements, real-time imaging and wide use across obstetrics, cardiology, abdominal imaging and point-of-care care. Portable systems and AI-guided acquisition expand access beyond traditional radiology departments.
Other imaging platforms include specialized nuclear, hybrid, mammography and niche systems represented within the report’s broader equipment scope. Demand is application-specific and often linked to specialty centers or advanced clinical programs.
Hospitals are the primary application segment because they combine emergency, inpatient, surgical, oncology, cardiovascular and specialty imaging demand with the capital base needed to operate multiple high-cost modalities.
Hospitals lead demand for MRI, CT, X-ray and ultrasound because imaging is embedded across emergency care, inpatient diagnosis, surgery, oncology and specialty pathways. Large health systems also purchase fleet management, service and software upgrades, increasing account value beyond the initial scanner transaction.
Independent diagnostic centers are important purchasers where outpatient imaging volumes support dedicated utilization. Their buying decisions are highly sensitive to throughput, uptime, patient convenience, payer mix and the ability to operate high-value scanners for extended hours.
Clinics favor modalities with smaller footprints and lower infrastructure requirements, particularly ultrasound and selected digital X-ray systems. Portable and automated products can expand this segment by reducing dependence on complex imaging departments.
Other applications include specialty facilities, mobile services and research environments. Demand is typically project-specific and driven by a defined clinical or scientific workflow rather than broad general imaging.
End-user segmentation reflects the clinical department that controls utilization and purchasing influence. Radiology remains the core end-user group, but cardiology and oncology are increasing their direct influence over modality specifications.
Radiology departments are the leading end users and manage the broadest modality mix. They prioritize image quality, protocol breadth, throughput, radiation safety, workflow integration, service responsiveness and compatibility with enterprise imaging systems.
Cardiology demand is increasing for advanced CT, echocardiography and MR applications that support coronary assessment, structural-heart planning and functional imaging. Recent product development is targeting simplified cardiac acquisition and one-beat CT workflows.
Oncology centers require imaging for detection, staging, treatment planning and follow-up. High-resolution CT and MRI, PET-linked workflows and radiation-therapy planning systems create demand for advanced multimodality platforms and precise longitudinal comparison.
Research institutions purchase high-field, advanced and specialized systems for clinical research and method development. Their requirements often emphasize raw-data access, advanced sequences, experimental flexibility and integration with analytical platforms.
Technology sophistication determines system price, clinical breadth and the type of provider that can justify the investment. Premium systems capture high value per unit, while mid-range and portable platforms expand volume and geographic reach.
High-end systems lead value because they combine premium detectors or magnets, faster acquisition, advanced reconstruction, AI-enabled workflow and specialty applications. Academic medical centers and major diagnostic networks are the primary buyers.
Mid-range platforms balance clinical capability with capital efficiency and form a broad replacement market across general hospitals and diagnostic centers. Suppliers compete through upgrade paths, service packages and standardized workflows.
Portable and entry-level systems expand imaging access in clinics, emergency settings, mobile services and developing healthcare markets. Their growth depends on ease of use, compact design, lower installation requirements and remote or automated support.
Equipment sales remain the dominant service model, but leasing and managed-equipment arrangements are becoming more relevant as providers seek predictable lifecycle cost and faster technology refresh.
Direct equipment purchase remains dominant among well-capitalized hospitals and diagnostic networks that want ownership, control over utilization and long-term asset planning. Major purchases commonly include installation, training and service agreements.
Leasing reduces the initial capital burden and can be attractive for growing diagnostic centers, temporary capacity needs or buyers that want shorter refresh cycles. The model transfers part of residual-value risk away from the provider.
Managed equipment services bundle fleet planning, maintenance, upgrades and performance management over multi-year periods. They are most relevant for large networks that prioritize uptime, standardization and lifecycle predictability across multiple imaging sites.
Regional market value depends on scanner density, procedure utilization, replacement cycles, reimbursement, healthcare capital spending and workforce availability. North America leads market value, while Asia-Pacific combines mature high-technology markets with large capacity-expansion opportunities.
North America leads the market through high utilization, large hospital and outpatient imaging networks, frequent technology replacement and early adoption of premium systems. The United States also has the second-highest MRI and PET scanner availability per capita among OECD countries, reinforcing the region’s high installed-base intensity.
Europe combines mature installed fleets with high examination volumes and structured capital replacement. OECD data show that Luxembourg, Austria, France and Portugal were among countries exceeding 370 combined CT, MRI and PET exams per 1,000 population in 2023, while MRI use in France rose strongly over the prior decade.
Asia-Pacific contains both world-leading installed bases and underpenetrated growth markets. OECD reports that Japan has the highest CT and MRI unit availability per capita, while Korea recorded more than 370 combined CT, MRI and PET exams per 1,000 population in 2023 and more than doubled CT and MRI exam volumes over 2013–2023.
Latin American demand is concentrated in major urban hospital and diagnostic networks. Capital constraints and currency volatility can slow premium-system replacement, increasing the relevance of mid-range equipment, refurbished assets, leasing and service models that reduce upfront expenditure.
The region combines high-value investment in Gulf healthcare systems with significant access gaps across lower-resource markets. WHO notes that many low- and lower-middle-income countries face equipment affordability and trained-workforce shortages, making robust systems, remote support and lower-infrastructure modalities commercially important.
Source: OECD Diagnostic technologies 2025; WHO medical imaging.
Diagnostic imaging systems operate under a combination of medical-device regulation, radiation-safety requirements and increasingly software-specific oversight. As equipment becomes more software-defined, regulatory capability is becoming a core part of product lifecycle management.
| Framework / Event | Requirement or Development | Commercial Relevance |
|---|---|---|
| FDA X-ray imaging requirements | X-ray, fluoroscopy and CT systems are subject to medical-device requirements and electronic-product radiation-control performance standards, including 21 CFR Parts 1010 and 1020. | Keeps dose optimization, quality controls and compliance engineering central to product design and procurement. |
| AI-enabled device authorization | FDA maintains a public list of authorized AI-enabled medical devices, with radiology representing a substantial and continuously updated portion of the list. | Demonstrates that AI is moving into regulated clinical products across acquisition, reconstruction and interpretation workflows. |
| AI Predetermined Change Control Plans | FDA’s August 2025 final guidance describes how manufacturers can propose planned AI device-software modifications, validation methods and impact assessments within a marketing submission. | Supports more structured lifecycle updates for AI-enabled imaging software while maintaining safety and effectiveness expectations. |
| Hospital cybersecurity & interoperability | Imaging systems increasingly connect to enterprise networks, cloud services, PACS and remote service platforms. | Raises the commercial importance of cybersecurity, software support and interoperability throughout the scanner lifecycle. |
Source: FDA Medical X-ray Imaging; FDA AI-enabled devices; FDA PCCP guidance.
The medical laboratory diagnostic imaging equipment market is highly competitive and technology-intensive. Global leaders combine broad modality portfolios, large installed bases and service networks, while specialist manufacturers compete through focused strength in mammography, ultrasound, digital radiography, preclinical imaging or cost-efficient systems.
Siemens Healthineers, GE HealthCare and Philips compete across multiple modalities and increasingly link hardware with workflow software, AI, enterprise services and long-term service contracts. Their installed bases create recurring upgrade and replacement opportunities.
Canon Medical, Hologic, Fujifilm, Shimadzu and other specialists defend share through modality-specific clinical strengths, detector technology, women’s health, radiography, ultrasound or advanced imaging niches.
Mindray, Samsung Medison and other Asia-based suppliers compete strongly in ultrasound and value-oriented imaging categories. Price-performance, compact systems, local manufacturing and service responsiveness are important in fast-growing markets.
Source: Siemens Healthineers; GE HealthCare; Philips.
July 2026: Philips launched the Alturion ultrasound system after FDA 510(k) clearance and CE marking. The system targets high-volume clinical environments with AI-powered workflow features, reinforcing the market shift toward automation that improves consistency and throughput.
September 2025: Siemens Healthineers announced the first U.S. installation of its Naeotom Alpha.Pro photon-counting CT system and stated that more than two million patients worldwide had been scanned with its photon-counting CT technology. The milestone shows photon-counting CT moving beyond early flagship deployment.
September 2025: GE HealthCare announced FDA 510(k) clearance for Revolution Vibe CT and the first global installation in France. The platform combines cardiac CT capability with AI-powered workflow and is positioned around faster, more consistent coronary imaging.
March 2025: Siemens Healthineers received FDA clearance for an expanded Naeotom Alpha class of photon-counting CT scanners, including a single-source system. The clearance broadened the commercial product range for a technology previously concentrated at the top end of CT.
February 2025: Philips launched SmartSpeed Precise for MRI with dual-AI engines and updated MR Workspace software across compatible 1.5T and 3.0T systems, focusing on faster scanning, image quality and throughput improvement.
Source: Philips Alturion; Siemens first U.S. Alpha.Pro installation; GE Revolution Vibe clearance; Siemens Naeotom FDA clearance; Philips SmartSpeed Precise.
The global medical laboratory diagnostic imaging equipment market market is projected to grow from USD 53.4 billion in 2026 to USD 74.4 billion by 2034, at a 4.2% CAGR during 2026–2034. Growth is expected to come from rising imaging utilization, replacement of aging installed systems, hospital and outpatient capacity expansion, and premiumization through photon-counting CT, AI-enabled workflow and faster MRI. Capital intensity, workforce shortages and pressure to demonstrate appropriate utilization will keep purchasing disciplined.
| Forecast Variable | Current Evidence / Starting Point | Expected Effect Through 2034 |
|---|---|---|
| Procedure utilization | OECD reports continued growth in CT and MRI use across several countries through 2023. | Supports replacement and additional capacity where scanner utilization remains high or waiting times are long. |
| Premium CT innovation | Photon-counting CT has expanded into broader commercial product classes with growing installed experience. | Raises average system value and accelerates premium CT replacement at advanced centers. |
| MRI productivity | AI-assisted reconstruction and workflow tools target shorter scans and higher throughput. | Allows providers to increase effective capacity and can strengthen the ROI case for upgrades. |
| Portable imaging | Ultrasound and mobile imaging can operate with lower infrastructure requirements than fixed high-end systems. | Expands the addressable market across clinics, emergency settings and lower-resource facilities. |
| Software lifecycle | FDA frameworks are evolving for AI-enabled device software updates and ongoing safety management. | Increases the importance of regulatory software capability, cybersecurity and post-sale upgrade support. |
The study is structured to support strategy, market-entry assessment, portfolio planning, competitive benchmarking and commercial opportunity analysis across the global medical laboratory diagnostic imaging equipment market landscape.
24LifeScience develops medical laboratory diagnostic imaging equipment market market estimates using a combination of bottom-up and top-down assessment. Bottom-up work reviews relevant manufacturers, product portfolios, geographic presence, installation or utilization patterns, commercial channels and pricing structure. Top-down work evaluates the addressable testing or diagnostic environment, installed capacity, procedure or production demand, replacement and upgrade cycles, and regional access conditions.
Primary research is used to validate market structure, purchasing criteria, technology adoption, competitive positioning and operating constraints where available. Secondary research prioritizes regulators, government and public-health agencies, recognized standards, peer-reviewed or professional evidence, and company filings or official product communications. Equipment and utilization evidence is checked against OECD and WHO data, FDA device and radiation-safety resources, and current primary manufacturer announcements; external market-research estimates are not used as evidence for the headline market framework.
Forecasts incorporate the 2025 market base, 2026 estimated conditions, technology and regulatory developments, replacement or expansion demand, regional investment, pricing pressure, service requirements and competitive intensity. High-impact assumptions are cross-checked against authoritative evidence before publication.
The market was valued at USD 51.3 billion in 2025 and is estimated at USD 53.4 billion in 2026. It is projected to reach USD 74.4 billion by 2034 at a 4.2% CAGR during 2026–2034.
MRI is the leading equipment type in the syndicated segmentation, supported by high-value systems, broad clinical utility and continued investment in faster acquisition, workflow automation and advanced magnet platforms.
North America is the largest regional market, supported by high scanner availability, strong utilization, large hospital and outpatient networks and early adoption of premium diagnostic-imaging technologies.
Asia-Pacific offers the strongest expansion opportunity because it combines highly developed imaging markets such as Japan and Korea with large capacity-growth markets including China and India.
Growth is driven by increasing imaging utilization, replacement of installed systems, early-diagnosis demand, hospital and outpatient capacity expansion, and technology upgrades in CT, MRI, ultrasound and digital X-ray.
AI is increasingly embedded in acquisition, reconstruction, protocol selection, measurements and workflow management. FDA continues to authorize AI-enabled radiology devices and has issued lifecycle guidance for planned software modifications.
High equipment and lifecycle costs, site requirements, radiation-management obligations for ionizing modalities, reimbursement discipline and shortages of trained imaging professionals can limit purchasing or utilization.
The study profiles Siemens Healthineers, GE HealthCare, Philips Healthcare, Canon Medical, Shimadzu, Fujifilm, Hologic, Carestream, Mindray, Samsung Medison, Hitachi Medical, Konica Minolta, Analogic, Planmeca and MR Solutions.
The standardized forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
